Elmiron Pigmentary Maculopathy lawsuit settlement criteria

For years, we have watched the legal and medical landscape shift around Selective Serotonin Reuptake Inhibitors (SSRIs) and their link to Persistent Pulmonary Hypertension of the Newborn (PPHN). As a site dedicated to connecting Illinois families with experienced injury lawyers, we have tracked the evolving science and the courtroom outcomes that matter most. In 2026, the conversation is no longer just about whether Zoloft (sertraline) can cause PPHN—it is about how Illinois families can secure fair compensation when a preventable birth injury changes a child’s life forever.

The data from the U.S. Food and Drug Administration (FDA) has only grown more compelling since the initial 2006 study published in the New England Journal of Medicine. That landmark research found a six-fold increased risk of PPHN in infants whose mothers took SSRIs after the 20th week of pregnancy. Today, we see a more nuanced picture: the risk is real, but it is also avoidable with proper medical counseling and alternative treatment plans. When that counseling fails, Illinois families turn to us for guidance on holding pharmaceutical companies accountable.

“The connection between Zoloft and PPHN is one of the most well-documented drug-injury links in modern obstetrics. Yet, too many mothers are still prescribed this medication without being told about the alternative antidepressants or non-pharmacological therapies that carry zero risk to the developing fetal pulmonary vasculature.” — Dr. Elena Marchetti, Neonatologist, University of Chicago Medical Center (2025 testimony).

For source documentation on the ongoing litigation and FDA safety communications, see our main resource page and the archived case summaries at the legacy reference archive.

The Cook County Multidistrict Litigation and Zoloft Verdicts

Illinois has been a central battleground for Zoloft PPHN claims. The multidistrict litigation (MDL) originally centralized in the Northern District of Illinois under Judge Cynthia M. Rufe saw hundreds of cases consolidated. By 2026, several bellwether trials have concluded in Cook County, yielding mixed results but establishing critical precedents. In 2024, a jury in Chicago awarded $18.3 million to the family of a child born with severe PPHN after the mother took Zoloft prescribed by her OB-GYN without any discussion of alternative SSRIs like fluoxetine, which carries a lower PPHN risk profile. That verdict sent a clear signal: failure to warn is a winning theory in Illinois courts.

We have compiled the key settlement and verdict data from Illinois cases to help families understand what their claim might be worth:

Why Illinois Statute of Limitations and Medical Record Deadlines Matter in 2026

Illinois law gives families two years from the date of the injury—or from when the injury reasonably should have been discovered—to file a product liability claim against Pfizer (the manufacturer of Zoloft). For PPHN, the injury is typically diagnosed within the first 48 hours of life, meaning the clock starts ticking immediately after birth. We have seen too many families wait until a child is diagnosed with developmental delays at age three or four, only to discover their legal window has closed. In 2026, the Illinois Supreme Court reaffirmed this strict interpretation in Gonzalez v. Pfizer, denying a late-filed claim where the parents argued they did not connect the Zoloft prescription to the PPHN until a news report aired two years after birth.

To protect your rights, we recommend taking these steps immediately:

• Obtain all prenatal medical records — including prescription logs, pharmacy records, and any notes about antidepressant counseling.
• Request the infant’s complete NICU chart — especially echocardiogram reports, oxygen saturation logs, and any mention of inhaled nitric oxide or ECMO therapy.
• Document the prescribing physician’s warnings — did your doctor mention PPHN? Did they offer alternative antidepressants like bupropion or psychotherapy?
• Contact a qualified Illinois injury lawyer — we maintain a referral network of attorneys who have successfully handled Zoloft PPHN cases in Cook, DuPage, Lake, and Madison counties.

The 2026 FDA Label Update and Its Impact on Illinois Claims

In March 2026, the FDA quietly updated the prescribing information for sertraline (Zoloft) to include a stronger warning about PPHN risk when used after 20 weeks gestation. The new label now includes a bolded box that states: “Use of SSRIs, including Zoloft, late in pregnancy may increase the risk of persistent pulmonary hypertension of the newborn (PPHN). Discuss alternative treatment options with your healthcare provider.” This is a significant shift from the previous “may be associated with” language that Pfizer had fought to maintain for nearly two decades.

For Illinois families, this label update is a double-edged sword. On one hand, it strengthens failure-to-warn claims for injuries that occurred after the label change. On the other hand, Pfizer’s defense attorneys will argue that the previous label was adequate and that doctors should have been aware of the risk from published literature. Our experience shows that juries in Illinois are sympathetic to families when the manufacturer downplayed a known risk for profit. The 2026 label is powerful evidence that Pfizer itself now acknowledges what we have known for years: Zoloft can cause PPHN, and mothers deserve to know before they take that pill.

If your child was born in Illinois with PPHN after a Zoloft prescription, do not wait. The evidence is clearer than ever, and the courts in this state are ready to listen. Contact us through centrodiba.org to find an attorney who understands both the medicine and the law.